Fundraising FoxMIVI Neuroscience
Eden Prairie, US · Founded 2014 · Delaware corporation
Find your way into MIVI Neuroscience
Sign up to see every warm intro you have to MIVI Neuroscience
- Paths you didn't know you had: your email and LinkedIn already hold routes to the MIVI Neuroscience team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
MIVI develops medical devices to improve outcomes in neurointerventional procedures, specifically targeting aspiration in distal stroke occlusions and reducing distal embolization during mechanical thrombectomy.
Founders & leadership
MO
Matthew OglePresident & CEO
Board
GF
George FazioBoard director
BC
Benjamin ConstableBoard director
JO
John O'MearaBoard director
Reported raises · per SEC filings
Form D private placements$67.4M disclosed across 9 rounds · 2017–2024
▶$510KraisedMay 2024 · 9 investors · Other Health CareRule 506(b)
▶$510KraisedMay 2024 · 9 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Craig YeshionDirector
- Nathan HarringtonDirector
- Tim HauchExecutive Officer
- Robert SternDirector
- Chris DeweyDirector
- Robert CollotonExecutive Officer, Director
- Taylor WhitmanDirector
- Offering amount
- $9.3M
- Amount sold
- $510K
- Sales commissions
- $250K
- Placement agents
- Ceros Financial Services, Inc.
- First sale
- May 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$9.6MraisedAug 2023 · 83 investors · Other Health CareRule 506(b)
▶$9.6MraisedAug 2023 · 83 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Craig YeshionDirector
- Nathan HarringtonDirector
- Tim HauchExecutive Officer
- Taylor WhitmanDirector
- Chris DeweyDirector
- Robert CollotonExecutive Officer, Director
- Robert SternDirector
- Offering amount
- $10M
- Amount sold
- $9.6M
- First sale
- Jul 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$45MraisedDec 2020 · 48 investors · Other Health CareRule 506(b)
▶$45MraisedDec 2020 · 48 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Robert CollotonExecutive Officer, Director
- Sean ChengDirector
- Craig YeshtonDirector
- Robert SternDirector
- Taylor WhitmanDirector
- Frederic MollDirector
- Offering amount
- $45M
- Amount sold
- $45M
- First sale
- Dec 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.2MraisedMar 2020 · 44 investors · Other Health CareRule 506(b)
▶$2.2MraisedMar 2020 · 44 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- James McCollumExecutive Officer, Director
- Benjamin ConstableDirector
- Christopher DeweyDirector
- Maurice FerreDirector
- Taylor WhitmanDirector
- Frederic MollDirector
- Matthew OgleExecutive Officer
- Offering amount
- $2.5M
- Amount sold
- $2.2M
- First sale
- Mar 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3.2MraisedFeb 2019 · 17 investors · Other Health CareRule 506(b)
▶$3.2MraisedFeb 2019 · 17 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Fred MollDirector
- James McCollumExecutive Officer, Director
- John O'MearaDirector
- Matthew OgleExecutive Officer, Director
- Benjamin ConstableDirector
- Offering amount
- $10M
- Amount sold
- $3.2M
- First sale
- Jan 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$500KraisedDec 2018 · 4 investors · Other Health CareRule 506(b)
▶$500KraisedDec 2018 · 4 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Fred MollDirector
- Matthew OgleExecutive Officer, Director
- John O'MearaDirector
- James McCollumExecutive Officer, Director
- Benjamin ConstableDirector
- Offering amount
- $1M
- Amount sold
- $500K
- First sale
- Nov 2018
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
▶$1.6MraisedSep 2017 · 27 investors · Other Health CareRule 506(b)
▶$1.6MraisedSep 2017 · 27 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Christopher GeyenExecutive Officer
- George FazioDirector
- Benjamin ConstableDirector
- Matthew OgleExecutive Officer, Director
- John O'MearaDirector
- Offering amount
- $1.6M
- Amount sold
- $1.6M
- First sale
- Sep 2017
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
▶$4MraisedAug 2017 · 1 investors · Other Health CareRule 506(b)
▶$4MraisedAug 2017 · 1 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Matthew OgleExecutive Officer, Director
- John O'MearaDirector
- George FazioDirector
- Benjamin ConstableDirector
- Christopher GeyenExecutive Officer
- Offering amount
- $4M
- Amount sold
- $4M
- First sale
- Aug 2017
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 1
Companies working in the same space as MIVI Neuroscience.
In the news
Frequently asked questions
- What does MIVI Neuroscience do?
- MIVI develops medical devices to improve outcomes in neurointerventional procedures, specifically targeting aspiration in distal stroke occlusions and reducing distal embolization during mechanical thrombectomy.
- How much funding has MIVI Neuroscience raised?
- MIVI Neuroscience has disclosed $67.4M raised across 9 rounds.
- Where is MIVI Neuroscience headquartered?
- MIVI Neuroscience is headquartered in Eden Prairie, US.